MedTech Dive October 15, 2025
As competitors have launched their first pulsed field ablation devices in the U.S., Abbott CEO Robert Ford told investors that the company is not just playing defense.
By the numbers
Q3 revenue: $11.37 billion
6.9% increase year over year
Net income: $1.64 billion
Flat year over year
As competitors continue to see success with their first pulsed field ablation systems in the U.S., Abbott is preparing to launch its own system next year.
Medtronic, Boston Scientific and Johnson & Johnson have already debuted PFA systems in the U.S. However, Abbott CEO Robert Ford told investors Wednesday that the company has not been playing defense.
“I don’t think it’s a question of...
Today's Sponsors
Today's Sponsor
Topics: Medical Devices